Tarveda Therapeutics is Drug Discovery in United States that focus on potent topoisomerase business. Founded in 2011. They cover business area such as developer, pentarin miniature drug conjugate medicine, a difference, patient, solid tumor malignancy, clinical evaluation, somatostatin receptor, neuroendocrine, small cell lung, company, cancer, potential toxicity.
2011
( 13 years old in 2024 )
Potent Topoisomerase
-
134 Coolidge Avenue
Watertown, MA 02472
United States
Private
developerpentarin miniature drug conjugate medicinea differencepatientsolid tumor malignancyclinical evaluationsomatostatin receptorneuroendocrine, small cell lungcompanycancerpotential toxicity
* We use standard office opening hours in near Tarveda Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Tarveda Therapeutics is Drug Discovery business from United States that founded in 2011 (13 years old in 2024), Tarveda Therapeutics business is focusing on Potent Topoisomerase.
Tarveda Therapeutics headquarter office and corporate office address is located in 134 Coolidge Avenue Watertown, MA 02472 United States.
Tarveda Therapeutics was founded in United States.
In 2024, Tarveda Therapeutics is currently focus on potent topoisomerase sector.
Above is snippet of Google Trends for "potent topoisomerase" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Tarveda Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
